Amaran Biotech, a subsidiary of Taiwan-based OBI Pharma, has signed a Memorandum of Understanding (MOU) with Nippon Fine Chemical and its subsidiary, Zillion Fine Chemicals.
The collaboration aims to enhance nanoparticle-based drug manufacturing and expand its presence in Taiwan, Japan, and international CDMO markets.
Amaran Biotech specialises in drug process development, analytical services, and cGMP manufacturing of high-value biopharmaceuticals.
The company operates Taiwan’s first fully automated robotic aseptic filling line, providing efficient solutions for high-value pharmaceuticals.
Under the partnership, Amaran will use its aseptic filling line to support Nippon’s production of nanoparticle-based drugs, including liposomes and lipid nanoparticles.
The company will also provide CDMO services, including sterile filtration, aseptic filling, packaging, storage, and quality management.
Amaran Biotech chairperson and general manager Tessie Che said: “Amaran continues to follow its motto of “Work Locally. Think and Act Globally.”
Amaran Biotech corporate strategy, business development and regulatory affairs vice president Ryan Lo said: “Amaran’s industry-leading aseptic filling line and extensive experience in pharmaceutical production have earned Nippon Fine Chemical’s trust.
“This collaboration not only provides a more comprehensive solution for nanoparticle-based drug CDMO but also aims to create synergistic business opportunities that multiply the value of our efforts.”
Nippon Fine Chemical, a Japanese company with over 40 years of expertise in phospholipids technology, offers drug carriers to improve drug targeting and stability.
Its Taiwan subsidiary, Zillion Fine Chemicals, is focused on liposome technology, and provides CRO and CDMO services.
The collaboration will enhance Zillion Fine Chemicals’ CDMO operations in Taiwan.
The three parties will work together to upgrade technology and services in the CDMO markets in Taiwan, Japan, and beyond.
Nippon Fine Chemical senior general manager Masaki Matsumoto said: “The nanoparticle-based drug market holds tremendous growth potential.
“We believe this partnership will inject significant momentum into our CDMO business development in Japan, Taiwan, and the global market.”
